MELBOURNE, AUSTRALIA and AUCKLAND, NEW ZEALAND--(Marketwire - October 09, 2007) - Living Cell Technologies Limited (ASX: LCT) (PINKSHEETS: LVCLY) today released positive preliminary results for its Phase I/IIa clinical trial of the company’s proprietary DiabeCell® porcine islet cell implant for the treatment of type 1 diabetes.
